|
 |
AloxiThis page contains recent news articles, when available, and an overview of Aloxi but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Aloxi (when available) Palonosetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Palonosetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. For the treatment of aausea and vomiting associated with cancer chemotherapy Mechanism Of Action: Palonosetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Palonosetron works by blocking the reception of serotonin at these 5-HT3 receptors. News Articles on Palonosetron Biovitrum Interim Report January 1st - September 30th, 2009 - Oct 21, 2009 Aloxi® was recommended by the Multinational Association for Supportive Care in Cancer and the European Society of Medical Oncology as the preferred 5-HT3 ... Ad-Hoc-News (Pressemitteilung) Riemser Arzneimittel AG auf gutem Kurs - Nov 10, 2009 Das gute Resultat lässt sich unter anderem auf sehr gute Leistungen des Onkologie-Force-Produktes Aloxi, ein starkes internationales Geschäft sowie ... Firmenpresse (Pressemitteilung) AP Pharma Reports Second Quarter 2009 Financial Results - Aug 4, 2009 The CR rates for patients receiving cisplatin based regimens were numerically higher for APF530 10 mg when compared to palonosetron (Aloxi®) in both acute PharmaLive.com (press release) FDA: More data needed on Glaxo nausea drug - Jun 23, 2009 If approved, Rezonic would compete with a few similar drugs, including Whitehouse Station, Merck & Co.'s Emend, Tokyo-based Eisai Co. Ltd.'s Aloxi and New The Associated Press Supportive Care in Cancer: Palonosetron Recommended 5-HT3 ... - Jun 30, 2009 Palonosetron has been developed by Helsinn Group of Switzerland and today it is marketed as Aloxi(R), Onicit(R), and Paloxi(R) in more than 40 countries SYS-CON Media (press release) Second Generation 5-HT3 Antagonists Open New Perspectives in ... - Jun 25, 2009 Palonosetron has been developed by Helsinn Group of Switzerland and today it is marketed as Aloxi(R), Onicit(R), and Paloxi(R) in more than 40 countries PR Newswire UK (press release) Expertos recomiendan el uso de 'Aloxi' (Italfarmaco) para prevenir ... - Jul 3, 2009 ...de 'Aloxi', apoyando su indicación para la prevención de los vómitos y náuseas agudas y diferidas causadas por quimioterapia moderadamente emetógena. ADN.es COMUNICADO: Cuidados paliativos en el cáncer: palonosetron es el ... - Jul 1, 2009 Palonosetron, comercializado como Aloxi(r), es la marca lÃder en EE.UU. dentro del segmento CINV Day of Chemo, y está creciendo consistentemente en los Europa Press Supportive Betreuung bei Krebs: MASCC/ESMO empfehlen Palonosetron ... - Jul 1, 2009 Palonosetron wurde von der Schweizer Firmengruppe Helsinn entwickelt und wird heute unter den Bezeichnungen Aloxi®, Onicit®, and Paloxi® in mehr als 40 news aktuell Schweiz (Pressemitteilung) FDA, GSK ì˜¤ì‹¬êµ¬í† ì™„í™”ì œ ë ˆì¡°ë‹‰ ì¶”ê°€ì •ë³´ 지시 - Jun 26, 2009 ...으로 ê°?소시키는 효과를 ë‚˜íƒ€ëƒˆë‹¤ê³ í•œë‹¤. ì•žìœ¼ë¡œë ˆì¡°ë‹‰ì?´ 허가ë?˜ë©´ 머í?¬ì?˜ ì?´ë©˜ë“œ(Emend: aprepitant), ì—?ì?´ìž?ì?´ì?˜ ì•Œë¡?ì‹œ(Aloxi: palonosetron) 등과 ê²½ìŸ?하게 ë?œë‹¤. 메디포뉴스 Soins de soutien pour les patients souffrant de cancer: Le ... - Jul 2, 2009 Le palonosétron a été développé par le Groupe suisse Helsinn et est aujourd'hui commercialisé sous le nom d'Aloxi®, Onicit® et Paloxi®, dans plus de 40 pays Presseportal.ch (Communiqué de presse) La seconde génération des antagonistes des 5-HT3 ouvre de ... - Jun 30, 2009 Le palonosetron a été mis au point par le groupe suisse Helsinn et est aujourd'hui commercialisé sous les noms Aloxi®, Onicit® et Paloxi® dans plus de 40 Presseportal.ch (Communiqué de presse) Palonosetron "Preferred" 5-HT3 Antagonist for Emesis Prevention in ... - Apr 2, 2009 Palonosetron, marketed as Aloxi(R), is the leading brand in the USA within the CINV Day of Chemo segment, and it is steadily growing in the European markets SYS-CON Media (press release) AP Pharma Announces Fourth Quarter and Year-End 2008 Financial ... - Mar 31, 2009 The 1395 patient trial compared the efficacy of APF530 with Aloxi(R) for the prevention of CINV following moderate or highly emetogenic chemotherapy. FOXBusiness MGI Pharma Inc - Strategic Analysis Review - companiesandmarkets ... - Apr 7, 2009 Currently, the company is commercializing Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen in the oncology and acute care segment across the US. PR-Inside.com (Pressemitteilung) Reportlinker Adds World Cancer Therapies Market Report - Apr 1, 2009 Receives EU Approval for mCRC Treatment With Erbitux II-58 MGI PHARMA and HELSINN Receive FDA Approval for Aloxi II-58 FDA Grants Approval for Sutent, Earthtimes (press release) Le palonosétron: l'antagoniste des 5-HT3 "privilégié" pour la ... - Apr 8, 2009 Le palonosétron a été développé par le groupe suisse Helsinn et est aujourd'hui commercialisé sous le nom d'Aloxi®, Onicit® et Paloxi®. Presseportal.ch (Communiqué de presse) Palonosetron "bevorzugter" 5-HT3-Rezeptorantagonist zur Vorbeugung ... - Apr 3, 2009 Palonosetron wurde von der Schweizer Firmengruppe Helsinn entwickelt und wird heute in Form der Arzneimittel Aloxi(R), Onicit(R) und Paloxi(R) vertrieben. news aktuell (Pressemitteilung) Le palonosétron garantit un apport calorique suffisant chez les ... - Mar 30, 2009 Le palonosétron, commercialisé sous le nom d'Aloxi(r), est la première marque aux États-Unis dans le secteur des antiémétiques administrés le jour de la InformationHospitaliere.com Aloxi® Superior to Kytril® for Delayed Nausea and Vomiting Due to ... - Feb 24, 2009 Researchers from Japan have reported that the combination of Aloxi® (palonosetron) and dexamethasone was as effective as Kytril® (granisetron) and Cancer Consultants Palonosetron safe, effective in preventing chemotherapy-induced ... - Jan 28, 2009 Researchers conducted a randomized, double blind, double-dummy trial comparing the second-generation 5HT3-receptor antagonist, 0.75 mg palonosetron (Aloxi, HemOncToday, Novo fármaco mais efectivo na prevenção de vómitos devido a ... - Jan 12, 2009 O Dr. Mitsue Saito e colegas, do Hospital Universitário de Juntendo, em Tóquio, relataram que o novo fármaco, o palonossetrom (comercalizado como Aloxi), Farmacia, Oncologists Rank Aloxi's Marketing Message Most Influential in the ... - Dec 4, 2008 Oncologists accurately identified Aloxi's messages with the brand, highlighting the strength of the Aloxi messaging campaign. According to the new report SYS-CON Media, Squashing a Queasy StomachHow to avoid nausea and vomiting during ... - Dec 23, 2008 The regimen includes a 5-HT3 antagonist—Anzemet (dolasetron), Kytril/Sancuso (granisetron), Zofran (ondansetron), or Aloxi (palonosetron)—given before Curetoday.com (press release), Helsinn Birex Pharmaceuticals Receives IMP Licence For Storage - Dec 14, 2008 The first packaging run has been completed for a study involving the Groups lead compound Palonosetron (ALOXI®, ONICIT®). Obtaining the IMP licence, Pharmaceutical Online (press release), AP Pharma Revises Target Date for APF530 NDA - Dec 18, 2008 ...to receive in the first chemotherapy treatment cycle either APF530 high dose (10mg), APF530 low dose (5mg) or the currently approved dose of Aloxi. WELT ONLINE, Non-Hodgkin Lymphoma & Supportive CareTreanda and Sancuso patch ... - Dec 23, 2008 Sancuso and other 5-HT3 inhibitors, such as Zofran (ondansetron) and Aloxi (palonosetron), interrupt that signal. Read more about management of nausea and Curetoday.com (press release), Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement ... - Nov 30, 2008 Helsinn's key products in the US are Aloxi® (palonosetron), distributed by Eisai Inc., USA, and Gelclair®. The active pharmaceutical ingredients and the PR-USA.net (press release), COMUNICADO: Helsinn Birex Pharmaceuticals recibe licencia IMP para ... - Dec 11, 2008 La primera operación de empaquetado se ha completado para un estudio que implicó el principal compuesto del grupo, Palonosetron (ALOXI(R), ONICIT(R)). Europa Press, ots.CorporateNews: Helsinn Healthcare SA / Helsinn Birex ... - Dec 11, 2008 Im Rahmen einer Studie mit Palonosetron (ALOXI(r), ONICIT(r)), dem führenden Präparat der Gruppe, wurde der erste Verpackungslauf bereits abgeschlossen. FOCUS Online, Helsinn Birex Pharmaceuticals obtient une licence IMP pour le ... - Dec 12, 2008 Le premier projet d'emballage a été complété pour une étude impliquant le composé principal Palonosetron (ALOXI®, ONICIT®) du Groupe. Presseportal.ch (Communiqué de presse), Helsinn Healthcare y Zealand Pharma firman un acuerdo de ... - Nov 28, 2008 UU. son Aloxi(R) (palonosetron), distribuidos por Eisai Inc., EE.UU., y Gelclair(R). Los ingredientes farmacéuticos activos y los productos farmacológicos PR Newswire UK (press release), ots.CorporateNews: Helsinn Healthcare SA / Helsinn Healthcare und ... - Nov 28, 2008 Zu den Schlüsselprodukten von Helsinn Healthcare in den USA gehören Aloxi® (Palonosetron), das von Eisai Inc., USA, vertrieben wird, und Gelclair®. FOCUS Online, Helsinn Healthcare et Zealand Pharma signent un accord de ... - Dec 3, 2008 Les produits phares de Helsinn Healthcare aux Etats-Unis sont Aloxi(R)( palonosétron, distribué par la société américaine Eisai Inc., et Gelclair(R). Caducée.net, AP Pharma Reports Results for the Third Quarter 2008 - Nov 5, 2008 Top-line data from the multi-center, randomized Phase 3 trial comparing APF530 with Aloxi(R) was previously released on September 30. FOXBusiness MattsonJack Study Reveals Cachexia Emerging as a Lucrative ... - Nov 20, 2008 ...by new branded agents such as Aloxi and the NK1 receptor antagonists, driving development activities to focus on reformulations of existing products. MarketWatch Premium Company Profile - MGI Pharma - New Research Report on ... - Nov 14, 2008 The company has five marketed products, namely Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen. The company’s major contributor to revenue growth during Live-PR.com (Pressemitteilung), MattsonJack Study Reveals Cachexia Emerging as a Lucrative ... - Nov 20, 2008 ...set by new branded agents such as Aloxi and the NK1receptor antagonists, driving development activities to focus onreformulations of existing products. International Business Times, Bumper outcome at IS Pharma - Nov 5, 2008 By David Blackwell IS Pharma, a supplier of speciality pharmaceuticals and medical devices to hospitals, more than doubled first-half pre-tax profits to Financial Times, MGI Pharma Inc - SWOT Analysis - New Research Report on Companies ... - Nov 15, 2008 The company markets cancer and acute care related pharmaceutical products such as Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen in the US. Live-PR.com (Pressemitteilung), AP Pharma Announces Positive Phase 3 Results with APF530 in the ... - Sep 30, 2008 The trial was structured to compare the two APF530 doses with Aloxi in four different assessments: acute and delayed onset CINV following both moderately WELT ONLINE, Homebuilder surges on amended credit facilities - Sep 30, 2008 AP Pharma says the 10mg dose of APF530 achieved complete response rates that were numerically higher than Aloxi across all four assessments, and the results Stockhouse, AP Pharma Inc. (APPA) Reveals Positive Phase III Results - Oct 1, 2008 ...“There is currently only one 5HT3 antagonist, Aloxi, that addresses both acute and delayed segments. We are delighted to have the second product to TransWorldNews (press release), AP Pharma Gets Mixed Results - Oct 7, 2008 AP Pharma’s pivotal Phase III study comparing the efficacy of APF530 (granisetron) with Aloxi for the prevention of chemotherapy-induced nausea and vomiting FDA news (subscription), Market Report -- In Play (APPA) - Sep 30, 2008 APF530 (the co's proprietary, sustained release formulation of granisetron) with Aloxi for the prevention of chemotherapy induced nausea and vomiting. MSN Money FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention ... Aug 23, 2008 ALOXI Capsules 0.5 mg for oral administration is indicated for the prevention of acute nausea and vomiting following initial and repeat courses ofMarketWatch Eisai Wins US Approval to Sell Nausea Drug Aloxi in Capsules Aug 24, 2008 25 (Bloomberg) -- Eisai Co. of Japan won US approval to sell a new capsule form of Aloxi, its medicine to prevent nausea and vomiting caused by surgery orBloomberg FDA Approvals: Nplate, Aloxi, Vidaza Sep 4, 2008 On August 22, the FDA approved an oral capsule formulation of palonosetron HCl (Aloxi; Eisai Corp) for the prevention of acute nausea and vomiting afterMedscape (subscription) Oral Form of Aloxi® Approved Aug 28, 2008 The United States Food and Drug Administration (FDA) has approved the oral capsule formulation of Eisai’s Aloxi® (palonosetron) for the prevention ofCancer Consultants, Aloxi capsules approved for chemotherapy-induced nausea and vomiting Aug 25, 2008 The FDA has approved a 0.5mg capsule formulation of Aloxi (palonosetron hydrochloride, from Eisai and Helsinn) for the prevention of chemotherapy-inducedPrescribing Reference, Palonosetron: The Long-lasting Antimetic Action Finds its Basis Sep 12, 2008 Palonosetron has been developed by Helsinn Healthcare SA of Switzerland and today it is marketed in more than 40 countries world-wide as Aloxi®, Onicit®,PharmaLive.com (press release), Podcast: Managing nausea and vomiting during chemotherapy Sep 13, 2008 The brand names for those, respectively, are Zofran, Kytril, Anzemet and Aloxi, and those will decrease nausea and vomiting quite a bit.MayoClinic.com Eisai obtains FDA clearance for Aloxi capsules Aug 25, 2008 Eisai has gained FDA approval to market a capsule version of Aloxi, a drug designed to prevent nausea due to surgery or chemotherapy.SmartBrief, エーザイã€?制å??剤「ALOXI(R) カプセルã€?ã€?米国ã?§ã?®æ‰¿èª?ã‚’å?–å¾—ã€?åŒ–å¦ ... Aug 24, 2008 ...今回承èª?ã?•ã‚Œã?Ÿã€ŒALOXI(R)カプセル0.5mgã€?ã?¯ã€?「åˆ?回ã?Šã‚ˆã?³å??復的ã?ªã€?ä¸ç‰åº¦ã?®å‚¬å??性を伴ã?†ã€?ã?Œã‚“化å¦ç™‚法ã?«ã‚ˆã‚‹æ€¥æ€§æ‚ªå¿ƒãƒ»å˜”å??(CINV)ã?®äºˆé˜²ã€?を効能・効果ã?¨ã?—ã?¦ã?„Japan Corporate News Network (プレスリリース), エーザイã?Œç¶šæ€¥ä¼¸ã€?ã?Œã‚“化å¦ç™‚法ã?«ã‚ˆã‚‹å‰¯ä½œç”¨ã‚’抑ã?ˆã‚‹çµŒå?£å‰¤ã?Œç±³å›½ã?§æ‰¿èª? Aug 24, 2008 ...エーザイ <4523> ã?Œç¶šæ€¥ä¼¸ã?—ã€?一時１４ï¼?円高ã?®ï¼”ï¼?ï¼—ï¼?円ã?¾ã?§è²·ã‚?ã‚Œã?¦ã?„る。２４日ã€?抗ã?Œã‚“剤ã?ªã?©ã€?ã?Œã‚“化å¦ç™‚法ã?§ç”Ÿã?˜ã‚‹å˜”å??ã?ªã?©ã?®å‰¯ä½œç”¨ã‚’軽減ã?•ã?›ã‚‹ã€Œï¼¡ï¼¬ï¼¯ï¼¸ï¼©æ ªå¼?æ–°è?ž, FDA, ì?¼ë³¸ ì—?ìž?ì?´ í•êµ¬í† ì œ ê²½êµ¬ì œí˜• 승ì?¸ Aug 26, 2008 ...ë¯¸êµ FDAê°€ ì?¼ë³¸ ì—?ìž?ì?´ì—? ì?˜í•´ 허가가 ì‹ ì²ë?˜ì—ˆë?˜ í•êµ¬í† ì œ ‘알ë¡?시’(Aloxi, palonosetron hydrochloride)ì?˜ 경구복용용 0.5mg 캡ìŠ?ì œí˜•ì—? 대해 발매를 승ì?¸í–ˆë‹¤.메디파나뉴스, Aloxi (palonosetron HCL) Injection Available for Prevention of ... - Jul 9, 2008 The introduction of ALOXI for PONV represents the first launch with an additional indication of an MGI PHARMA, INC. product since Eisai acquired the PharmaLive.com (press release), Aloxi now available for post-op nausea and vomiting - Jul 9, 2008 Eisai and Helsinn have launched Aloxi (palonosetron HCl injection), a selective 5-HT 3 receptor antagonist for the prevention of postoperative nausea and Prescribing Reference, HAIR STYLIST - Jul 9, 2008 We use Wella and Aloxi color lines. We also apply impermanent weaves and extensions. I really enjoy my work, and since I sold my salon I can enjoy doing Asbury Park Press, Helsinn Healthcare SA anuncia el lanzamiento de la inyección de ... - Jul 10, 2008 UU. de la inyección de ALOXI(R) (hidrocloruro de palonosetrón) de 0075 mg para la prevención de náuseas y vómitos postoperatorios (PONV) durante un máximo Finanzas.com, Helsinn Healthcare SA gibt die Einführung von ALOXI® (Palonosetron ... - Jul 10, 2008 Lugano, Schweiz (ots) - Das Top-Management von Helsinn und sein US-Partner Eisai Inc. gaben heute die Verfügbarkeit von of ALOXI® (Palonosetron news aktuell (Pressemitteilung), Helsinn Healthcare SA annonce la commercialisation aux États-Unis ... - Jul 10, 2008 Cette nouvelle indication d'ALOXI® pour NVPO représente la première mise sur le marché d'un produit MGI Pharma depuis le rachat de la société par Eisai en Presseportal.ch (Communiqués de presse), エーザイã€?「ＡＬＯＸＩ 注射剤ã€?ã?«è¡“後ã?®æ‚ªå¿ƒãƒ»å˜”å??予防ã?®åŠ¹èƒ½ãƒ»åŠ¹æžœ ... - Jul 8, 2008 ...ＡＬＯＸＩ（Ｒ）ã?¯ã€?ï¼’ï¼?ï¼?８年２月２９日ã?«ï¼¦ï¼¤ï¼¡ï¼ˆç±³å›½é£Ÿå“?医薬å“?局）よりＰＯＮＶ予防ã?®åŠ¹èƒ½ãƒ»åŠ¹æžœã?®è¿½åŠ 承èª?ã‚’å?–å¾—ã?—ã?¾ã?—ã?Ÿã€‚本剤ã?¯ã€?術後２４時間ã?¾ã?§ã?®ï¼°ï¼¯ï¼®ï¼¶ 日経プレスリリース, 美国FDA批准第二代5-HT3å?—体拮抗剂Aloxi新适应è¯? - Jul 10, 2008 ...美国食å“?è?¯å“?管ç?†å±€ï¼ˆFDA）日å‰?已批准Helsinn Healthcareå…¬å?¸çš„第二代5-HT3å?—体拮抗剂Aloxi ä¸å›½åŒ»è?¯ç½‘, Brand Names/Synonyms: Aloxi is also known by the following brand names and/or synonyms: Aloxi; Onicit; Palonosetron; Raloxifene Drug Category: Aloxi is categorized under the following by the FDA: Antiemetics; ATC:A04AA Dosage Forms: Not Available Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
